All In Biotech

Drug Trial Radar · NCT07774325

A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood

The Effects of P-gp Inhibition and OATP Inhibition on the Pharmacokinetics of a Single Oral Dose of BI 3000202 in Healthy Male Trial Participants (an Open-label, Three-period, Two-sequence Crossover Trial, With Period 3 as Fixed Treatment)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Sep 1, 2026

Primary completion

Oct 11, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this trial is to investigate the effects of multiple doses of Itraconazole and multiple doses of Ciclosporin on the pharmacokinetics of BI 3000202 in plasma following a single oral dose in healthy male trial participants.

Conditions

  • Healthy

Interventions

  • BI 3000202Drug

    BI 3000202

  • CiclosporinDrug

    Ciclosporin

  • ItraconazoleDrug

    Itraconazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)Time frame: up to 4 days
  2. Maximum measured concentration of the analyte in plasma (Cmax)Time frame: up to 4 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Humanpharmakologisches Zentrum Biberach

    Biberach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.